Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Randomized Trial Evaluating the Efficacy and Safety of Two Dosages of Once Daily Oral CA-170 in Patients with Selected Relapsed Advanced Tumors (ASIAD)

Trial Profile

A Phase 2, Open-Label Randomized Trial Evaluating the Efficacy and Safety of Two Dosages of Once Daily Oral CA-170 in Patients with Selected Relapsed Advanced Tumors (ASIAD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2019

At a glance

  • Drugs CA 170 (Primary)
  • Indications Head and neck cancer; Hodgkin's disease; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Aurigene Discovery Technologies
  • Most Recent Events

    • 07 Nov 2018 According to a Curis media release, data from this trial will be presented at the 33rd Society for Immunotherapy of Cancer Annual Meeting
    • 02 Aug 2018 According to a Curis media release, Aurigene is continuing patient enrolment at select sites in India, additional updates are expected in 2H 2018.
    • 08 Mar 2018 Status changed from planning to recruiting, according to a Curis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top